

Kennedy Joseph T  
Form 4  
July 03, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kennedy Joseph T

(Last) (First) (Middle)

C/O AMARIN PHARMA, INC., 1430 ROUTE 206

(Street)

BEDMINSTER, NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

AMARIN CORP PLC\UK [AMRN]

3. Date of Earliest Transaction (Month/Day/Year)

06/30/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)

General Counsel

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4)  |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|------------------------------------|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                    |
| Ordinary Shares <sup>(1)</sup>  | 06/30/2018                           |  | M                              |   | 47,187 <sup>(2)</sup>   | A  | <u>(3)</u> 65,621 <sup>(4)</sup> D |
| Ordinary Shares <sup>(1)</sup>  | 06/30/2018                           |  | M                              |   | 6,250 <sup>(5)</sup>  | A  | <u>(3)</u> 71,871 <sup>(4)</sup> D |
| Ordinary Shares <sup>(1)</sup>  | 06/30/2018                           |  | F <sup>(6)</sup>               |   | 26,495  | D  | \$ 3.09 45,376 <sup>(4)</sup> D    |
| Ordinary Shares <sup>(1)</sup>  | 07/02/2018                           |  | S <sup>(7)</sup>               |   | 26,942  | D  | \$ 3.0048 18,434 <sup>(4)</sup> D  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.



## Edgar Filing: Kennedy Joseph T - Form 4

- (3) Not applicable.
- (4) Please see the section titled "Remarks" below for additional information.
- (5) As previously reported on October 6, 2015, the Reporting Person was granted 100,000 RSUs under the Plan. These RSUs vest in 16 equal quarterly installments. The twelfth vesting event occurred on June 30, 2018.
- (6) Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
- (7) Sales made pursuant to a 10b5-1 trading plan dated December 9, 2016.  
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.92 to \$3.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- (9) Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.

### **Remarks:**

In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. As of the date of the

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.